Latest Breaking News On - Igard trial - Page 1 : comparemela.com

Year-End Report, 2020 Positive Topline Results from Pivotal Phase 3 NefIgArd Trial “On November 8, 2020, we announced positive topline readout of Part A of our Phase 3 pivotal trial, NefIgArd. The results were statistically significant and clinically relevant: proteinuria showed a 31% reduction versus baseline, a stronger effect than what was seen in the Phase 2b (27%), which is generally not expected when moving from Phase 2 to Phase 3. In addition, eGFR was stabilised in the treated patient population, which in the end is the true treatment goal. This potentially disease modifying effect is to our knowledge unique to Nefecon, which we find extremely exciting, and we look forward to our interactions with regulators during the year as we progress towards potential approval.

United statesUnited kingdomRenee aguiar lucanderMikael widellYear end reportTopline resultsPivotal phaseIgard trialPresentation februaryAnnual reportNasdaq stockholmNasdaq global select marketஒன்றுபட்டது மாநிலங்களில்ஒன்றுபட்டது கிஂக்டம்மைக்கேல் வீடேல்ல்ஆண்டு முடிவு அறிக்கை